John Bencich
2022
In 2022, John Bencich earned a total compensation of $1.5M as Chief Executive Officer at OncoGenex Pharmaceuticals, a 7% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $223,125 |
---|---|
Option Awards | $358,670 |
Salary | $510,000 |
Stock Awards | $413,000 |
Total | $1,504,795 |
Bencich received $510K in salary, accounting for 34% of the total pay in 2022.
Bencich also received $223.1K in non-equity incentive plan, $358.7K in option awards and $413K in stock awards.
Rankings
In 2022, John Bencich's compensation ranked 2,222nd out of 5,736 executives tracked by ExecPay. In other words, Bencich earned more than 61.3% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,222 | 61st |
Manufacturing | 1,205 | 61st |
Chemicals And Allied Products | 528 | 63rd |
Drugs | 486 | 63rd |
In Vitro and In Vivo Diagnostic Substances | 6 | 79th |
Bencich's colleagues
We found two more compensation records of executives who worked with John Bencich at OncoGenex Pharmaceuticals in 2022.
News
OncoGenex Pharmaceuticals CEO John Bencich's 2022 pay slips 7% to $1.5M
April 28, 2023
OncoGenex Pharmaceuticals CEO John Bencich's 2021 pay jumps 82% to $1.6M
April 21, 2022
OncoGenex Pharmaceuticals CEO Richard Stewart's 2020 pay jumps 30% to $1M
March 30, 2021
OncoGenex Pharmaceuticals CEO Richard Stewart's 2019 pay falls 27% to $797K
April 2, 2020
OncoGenex Pharmaceuticals CEO Richard Stewart's 2018 pay jumps 423% to $1.1M
March 28, 2019